Claims for Patent: 7,964,219

Summary for Patent: 7,964,219

Title:	Pharmaceutical compositions for controlled release delivery of biologically active compounds
Abstract:	The present invention provides compositions and methods for the controlled release delivery of one or more biologically active compounds to a subject. Specifically, the invention provides for a pharmaceutical composition for the controlled release delivery of biologically active compounds to a subject comprising: a) a complex of a biologically active compound having at least one basic functional group and a polyanion derived from hexahydroxycyclohexane having at least two negatively charged functional groups; and b) a pharmaceutically acceptable carrier comprising a biodegradable, water-insoluble polymer. By complexing a biologically active compound with a polyanion, the tight, stable complex may be incorporated into a long-acting dosage system having a more desired drug release curve over time than that is found in the prior art. The invention also provides the methods of making such compositions and the methods of use thereof.
Inventor(s):	Li; Yuhua (Newark, DE), Chien; Benjamin (Newark, DE)
Assignee:	QPS, LLC (Newark, DE)
Application Number:	11/201,932
Patent Claims:	1. A pharmaceutical composition comprising: a) an ionic complex that is formed between i) a biologically active compound having at least one basic, positively charged functional group and ii) a polyanion that is inositol hexaphosphate or inositol hexasulphate; and b) a pharmaceutically acceptable carrier comprising a biodegradable, water-insoluble polymer. 2. The pharmaceutical composition of claim 1 wherein the inositol is selected from the group consisting of cis-inositol, epi-inositol, allo-inositol, neo-inositol, myo-inositol, muco-inositol, scyllo-inositol, L-(-)-chiro-inositol, and D-(+)-chiro-inositol. 3. The pharmaceutical composition of claim 1 wherein the inositol is myo-inositol. 4. The pharmaceutical composition of claim 1 wherein the polyanion is inositol hexaphosphate. 5. The pharmaceutical composition of claim 1 wherein the polyanion is inositol hexasulphate. 6. The pharmaceutical composition of claim 1 wherein the biologically active compound has at least one basic nitrogen. 7. The pharmaceutical composition of claim 6 wherein the basic nitrogen is selected from the group consisting of amine, imine and ring nitrogen. 8. The pharmaceutical composition of claim 1 wherein the biologically active compound is selected from the group consisting of small molecules, macromolecules, peptides, proteins, and enzymes. 9. The pharmaceutical composition of claim 1 wherein the biologically active compound is selected from the group consisting of doxorubicin, diltiazam, cyclobenzaprine, noscapine, nortriptyline, quinidine, ergotamine, benztropine, verapamil, flunarizine, imipramine, pyrimethamine, naltrexone, lidocaine, prilocaine, mepivacaine, bupivacaine, tetracaine, ropivacaine, oxytocin, vasopressin, adrenocorticotropic hormone (ACTH), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), prolactin, luteinising hormone, luteinizing hormone releasing hormone (LHRH), LHRH agonists, LHRH antagonists, growth hormones (including human, porcine, and bovine), growth hormone releasing factor, insulin, erythropoietin (including all proteins with erythropoietic activity), somatostatin, glucagon, interleukin, interferon-.alpha., interferon-.beta., interferon-.gamma., gastrin, tetragastrin, pentagastrin, urogastrone, secretin, calcitonin, enkephalins, endorphins, angiotensins, thyrotropin releasing hormone (TRH), tumor necrosis factor (TNF), parathyroid hormone (PTH), nerve growth factor (NGF), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), macrophage-colony stimulating factor (M-CSF), heparinase, vascular endothelial growth factor (VEG-F), bone morphogenic protein (BMP), hANP, glucagon-like peptide (GLP-1), exenatide, peptide YY (PYY), renin, bradykinin, bacitracins, polymyxins, colistins, tyrocidine, gramicidins, cyclosporins (which includes synthetic analogues and pharmacologically active fragments thereof), enzymes, cytokines, vaccines, antibiotics, antibodies, glycoproteins, follicle stimulating hormone, kyotorphin, taftsin, thymopoietin, thymosin, thymostimulin, thymic humoral factor, serum thymic factor, colony stimulating factors, motilin, bombesin, dinorphin, neurotensin, cerulein, urokinase, kallikrein, substance P analogues and antagonists, angiotensin II, blood coagulation factor VII and IX, lysozyme, gramicidines, melanocyte stimulating hormone, thyroid hormone releasing hormone, thyroid stimulating hormone, pancreozymin, cholecystokinin, human placental lactogen, human chorionic gonadotrophin, protein synthesis stimulating peptide, gastric inhibitory peptide, vasoactive intestinal peptide, and platelet derived growth factor. 10. The pharmaceutical composition of claim 8 wherein the biologically active compound is selected from the group consisting of doxorubicin, rapamycin, naltrexone, epidermal growth factor (EGF), LHRH agonists, LHRH antagonists, growth hormones, growth hormone releasing factor, octreotide, interferon-alpha, interferon-beta, interferon-gamma, calcitonin, parathyroid hormone (PTH), glucagon-like peptide (GLP-1), and peptide YY (PYY). 11. The pharmaceutical composition of claim 1 wherein the biologically active compound is doxorubicin. 12. The pharmaceutical composition of claim 1 wherein the biologically active compound is glycagon like peptide 1 (GLP-1) and its analogues. 13. The pharmaceutical composition of claim 1 wherein the biologically active compound is Octreotide. 14. The pharmaceutical composition of claim 1 wherein the biologically active compound is peptide YY (PYY). 15. The pharmaceutical composition of claim 1 wherein the biodegradable, water insoluble polymer is selected from the group consisting of polylactides, polyglycolides, poly(lactide-co-glycolide)s, polycaprolactones, polydioxanones, polycarbonates, polyhydroxybutyrates, polyalkylene oxalates, polyanhydrides, polyamides, polyesteramides, polyurethanes, polyacetals, polyorthocarbonates, polyphosphazenes, polyhydroxyvalerates, polyalkylene succinates, polyorthoesters, and copolymers, block copolymers, branched copolymers, terpolymers and combinations and mixtures thereof. 16. The pharmaceutical composition of claim 1 wherein the pharmaceutically acceptable carrier comprises an environment responsive polymer or gel. 17. The pharmaceutical composition of claim 16 wherein the environment responsive polymer or gel is thermosensitive, pH sensitive, or electrically sensitive. 18. The pharmaceutical composition of claim 1 in the form selected from the group consisting of injectable solutions or suspensions, particles, films, pellets, cylinders, discs, microcapsules, microspheres, nanospheres, microparticles, wafers, micelles, and liposomes. 19. The pharmaceutical composition of claim 9 wherein the antibiotic is selected from the group consisting of doxycyclin, bacitracin, erythromycin, polymyxin, vancomycin, gentamycin, kanamycin, neomycin, amoxicillin, amikacin, arbekacin, bambermycins, butirosin, dibekacin, dihydrostreptomycin, fortimicin, isepamicin, micronimicin, netilmicin, paromycin, ribostamycin, rapamycin, sisomicin, streptomycin and tobramycin.

Details for Patent 7,964,219

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2024-08-12
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2024-08-12